Latest issue
Daily issue/
Loading page…
Superpower Daily briefing
The daily AI briefing.
One concise market read on the models, products, companies, and decisions moving AI.
What we cover
AI coverage with a market filter.
Superpower Daily is not a generic link dump. It is a daily read on the AI moves that affect product decisions, startup strategy, policy risk, GTM timing, and where attention is shifting.
Models
Launches, pricing changes, capability jumps, benchmark movement, and model strategy.
Products
AI features, apps, agents, creative tools, enterprise products, and workflow shifts.
Startups
Funding rounds, acquisitions, founder moves, category formation, and early market traction.
Business
Platform strategy, partnerships, adoption signals, earnings commentary, and buyer behavior.
Policy
Lawsuits, copyright fights, regulation, safety debates, government action, and labor impact.
Culture
Viral AI moments, social behavior, creator tools, public reaction, and weird edge cases.
Subscribe
Join 350k readers who want the point, not the firehose.
- Know what changed in AI without reading ten feeds.
- Separate market-moving stories from launch-day noise.
- See how models, products, startups, policy, and culture connect.
- Use the Latest page when a story deserves deeper reading.
No spam. Just the AI moves worth knowing.
Signal scan
Daily
One concise market read
Briefing archive
Read what the briefing looks like.
Start with the latest issue, then scan recent coverage before you subscribe.
Showing 1-8 of 664 issues
Browse by area
Follow the parts of AI that matter to you.
The daily read stays broad, while the Latest page lets you focus on models, products, startups, policy, tools, business, or culture.
Models
Newer Google and OpenAI image models were easier to bypass, White Circle researchers say
3 stories
Products
ServiceNow adds verifiable AI agent identities alongside new automation tools
3 stories
Tools
Check Point discloses LiteLLM flaws that enabled gateway takeover and API-key theft
3 stories
Startups
Ramp raises $1.85 billion at a $60 billion valuation as its AI ambitions grow
3 stories
Business
AstraZeneca commits $40 million to insitro for AI-led drug discovery
3 stories
